TS-121
| Clinical data | |
|---|---|
| Synonyms | TS-1211 |
| Routes of administration | Oral |
TS-121 is an orally active, selective vasopressin V1B receptor antagonist[1] which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3] As of May 2017, it is in phase II clinical trials for this indication.[2][3]
See also
References
External links
- TS-121 - AdisInsight
- New Drug Pipeline - Taisho Pharmaceutical
- A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder - ClinicalTrials.gov
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.